Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1 1b Clinical Trial Of Itk Inhibitor Cpi 818 In China is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China
BURLINGAME, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus